GlassScriptPhysician profile
Charles D Whiting
NPI 1992867956
$5,275.17
in general payments reported to CMS, 2019-2025
26 companies · $2,006 in 2025
The $2,006 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $644 · 2023: $1,009 · 2024: $1,459 · 2025: $2,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,300 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,299.69 |
| Education | $174.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,878.99 | 2021-2025 | |
| Janssen Biotech, INC. | $584.21 | 2022-2025 | Tremfya, Stelara, Simponi |
| Phathom Pharmaceuticals, INC. | $445.83 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $355.79 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.49 | 2022-2025 | Xifaxan, Plenvu |
| Celgene Corporation | $216.91 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $199.43 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $190.37 | 2023-2025 | Entyvio |
| Aimmune Therapeutics, INC. | $166.47 | 2024-2025 | Zenpep, Vowst |
| Genzyme Corporation | $143.15 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $114.44 | 2024-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $98.24 | 2023-2025 | Ocaliva |
| Pfizer INC. | $89.99 | 2022-2025 | |
| Celltrion USA INC. | $86.24 | 2024-2025 | Zymfentra, Vegzelma |
| Nestle Healthcare Nutrition INC. | $73.09 | 2022-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $48.14 | 2023-2024 | Linzess |
| Gilead Sciences, INC. | $47.42 | 2025 | |
| Janssen Scientific Affairs, LLC | $46.22 | 2025 | Tremfya |
| Novo Nordisk INC | $43.98 | 2024 | Wegovy |
| Mallinckrodt Hospital Products INC. | $41.85 | 2023-2025 | Terlivaz |
| Astrazeneca Pharmaceuticals LP | $26.66 | 2025 | |
| Daiichi Sankyo INC. | $23.95 | 2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.94 | 2023 | Cyltezo |
| Ferring Pharmaceuticals INC. | $16.98 | 2025 | Rebyota |
| Madrigal Pharmaceuticals | $15.72 | 2025 | Rezdiffra |
| Lucid Diagnostics INC. | $14.67 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Whiting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.